• Home
  • Biopharma
  • Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?
Image

Will Veeva and Amgen’s $50 Billion Industry Push Set a New Global Standard for Technology-Driven Clinical Trials?

Key Highlights:

  • Veeva Systems partners with Amgen to deploy its end-to-end Clinical Platform across global trials.
  • Collaboration aims to accelerate new medicine development by streamlining trial operations with advanced digital tools.
  • Marks a pivotal industry shift toward technology-driven clinical trial innovation, promising faster patient access to breakthrough therapies.

Collaboration to Accelerate Clinical Development
Veeva Systems announced a landmark collaboration with Amgen to transform clinical trial execution through the adoption of the Veeva Clinical Platform. By integrating this connected ecosystem across operations, Amgen aims to identify new efficiencies, improve trial oversight, and accelerate timelines for delivering novel treatments. This collaboration highlights how technology and biotech leadership are converging to advance medicine at scale.

Digital Backbone for End-to-End Trials
The Veeva Clinical Platform offers a comprehensive suite including CTMS, EDC, CDB, RTSM, eCOA, eTMF, Site Connect, and Study Training. Together, these tools create a unified data flow that streamlines every phase of a trial, from start-up through closeout. With automated processes and standardized workflows, Amgen expects to unlock new levels of agility while reducing operational complexity across its global research footprint.

Driving Innovation With Strategic Business Consulting
Beyond technology, Veeva Business Consulting will guide Amgen in implementation and change management, ensuring seamless integration into existing operations. This strategic support is expected to maximize value realization, enabling Amgen to deliver faster, smarter, and more patient-focused trials. The partnership reflects a shared vision to combine cutting-edge platforms with expert-driven transformation.

Company Commitments to Patients and Industry
For Amgen, the collaboration reinforces its mission of accelerating the development of medicines for serious diseases through innovation and scale. For Veeva, it further validates its role as the digital backbone of modern life sciences, trusted by more than 1,500 biopharma customers worldwide. Together, the two companies are setting a new industry benchmark for how advanced platforms can reshape the clinical trial ecosystem and ensure patients benefit sooner from medical breakthroughs.

About Veeva Systems
Veeva Systems (NYSE: VEEV) is a global leader in cloud-based solutions for the life sciences industry, delivering software, data, and business consulting that empower over 1,500 companies, from top biopharma to emerging biotech. As a Public Benefit Corporation, Veeva is committed to balancing customer success with stakeholder value, innovation, and industry transformation.

About Amgen
Amgen is one of the world’s leading biotechnology companies, focused on discovering, developing, and delivering innovative medicines that address serious diseases. With a robust pipeline and global presence, Amgen combines cutting-edge science with a commitment to patients, pioneering breakthroughs across oncology, immunology, and rare diseases.

Releated Posts

OmniAb and Eli Lilly Announce $370M Global Collaboration to Discover Antibody-Based Therapeutics Targeting Ion Channels

Emeryville, Calif. and Indianapolis, Ind. — August 17, 2026 — OmniAb, Inc. (NASDAQ: OABI), a leading provider of…

ByByAnuja Singh Aug 21, 2026

Sandoz’s $314M Bet on Chinese Biosimilars Targets a Drug the Industry Couldn’t Crack for a Decade

Inside the Sandoz-Henlius licensing deal for biosimilars of Repatha, Benlysta, and Erbitux — and why one of the…

ByByAnuja Singh Aug 21, 2026

Merck and Moderna’s Melanoma Vaccine Win Could Be the Proof Point mRNA Oncology Has Been Waiting For

What the Phase 3 intismeran autogene + Keytruda results mean for the next wave of personalized cancer vaccines…

ByByAnuja Singh Aug 21, 2026

Most-Favored-Nation Pricing: How U.S. Drug Prices Are Being Reset

A quick-read guide to the Trump administration’s MFN pricing policy and what it means for biopharma GLOBAL BIOPHARMA…

ByByAnuja Singh Aug 1, 2026
Scroll to Top